BIO-B:NYE-Bio-Rad Laboratories Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 225.29

Change

0.00 (0.00)%

Market Cap

USD 6.39B

Volume

112.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-1.74 (-1.36%)

USD 220.05B
MDT Medtronic PLC

-1.85 (-2.20%)

USD 106.32B
ZBH Zimmer Biomet Holdings Inc

-4.70 (-4.61%)

USD 22.25B
STE STERIS plc

-2.97 (-1.33%)

USD 22.15B
SNN Smith & Nephew SNATS Inc

-0.02 (-0.08%)

USD 11.31B
PEN Penumbra Inc

+1.99 (+0.74%)

USD 10.50B
GMED Globus Medical

-0.63 (-0.86%)

USD 9.77B
BIO Bio-Rad Laboratories Inc

-4.64 (-1.86%)

USD 6.94B
GKOS Glaukos Corp

+1.61 (+1.73%)

USD 5.78B
INSP Inspire Medical Systems Inc

-3.46 (-2.31%)

USD 4.39B

ETFs Containing BIO-B

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.81% 20% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.81% 20% F 8% B-
Trailing 12 Months  
Capital Gain -33.45% 35% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.45% 35% F 10% F
Trailing 5 Years  
Capital Gain -45.05% 20% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.05% 20% F 7% C-
Average Annual (5 Year Horizon)  
Capital Gain -8.29% 33% F 8% B-
Dividend Return -8.29% 30% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.26% 67% D+ 37% F
Risk Adjusted Return -30.41% 27% F 9% A-
Market Capitalization 6.39B 73% C 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector